We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
Read MoreHide Full Article
Key Takeaways
KYMR reported positive phase I results for KT-621, showing strong STAT6 degradation in blood and skin
The oral STAT6 degrader matched or outperformed Dupixent on Th2 biomarkers like TARC and Eotaxin-3.
KT-621 showed a placebo-like safety profile with no serious adverse events across escalating dose cohorts
Kymera Therapeutics, Inc. (KYMR - Free Report) announced positive clinical results from the phase I study on the investigational candidate, KT-621.
Shares surged as data surpassed the company’s expectations and showed comparable efficacy to Dupixent (dupilumab).
KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Th2 inflammation.
Shares of KYMR have gained 7.2% year to date against the industry’s decline of 2.2%.
Image Source: Zacks Investment Research
More on KYMR’s Study on KT-621
The phase I study was a double-blind, placebo-controlled study that enrolled a total of 118 subjects. The trial consisted of single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. The objective was to evaluate the safety and tolerability of escalating single and multiple ascending daily oral doses of KT-621.
The study also included pharmacokinetic measures as secondary endpoints.
Data showed KT-621 demonstrated a favorable plasma PK profile after single and multiple doses. There was a dose-proportional increase in exposure after multi-dosing, and steady-state was achieved by day four.
The candidate also demonstrated rapid, deep and prolonged STAT6 degradation in blood after single doses of KT-621 and in blood and skin after multiple doses of KT-621.
A greater than 90% mean STAT6 degradation in blood was achieved at all doses above 1.5 mg and complete STAT6 degradation was achieved in both blood and skin at all MAD doses greater than 50 mg.
Data surpassed Kymera’s target product profile, significantly derisking the program and further validating its oral, biologics-like profile.
The impact on Th2 biomarkers was in line or superior to Dupixent with median TARC reduction up to 37% and median Eotaxin-3 reduction up to 63%.
Dupixent is a blockbuster asthma and dermatitis drug being marketed by Sanofi (SNY - Free Report) and Regeneron.
KT-621 was well-tolerated with a safety profile undifferentiated from placebo. There were no serious adverse events, no severe adverse events and no treatment-related adverse events in more than one subject, and no clinically relevant changes in vital signs, lab tests or ECGs.
In April, Kymera initiated dosing in the KT-621 BroADen phase Ib study in moderate to severe atopic dermatitis (AD) patients. Data is expected to be reported in the fourth quarter of 2025. Two parallel phase IIb studies in AD and asthma are set to start in the fourth quarter of 2025 and first quarter of 2026, respectively.
Kymera intends to accelerate KT-621 development and enable dose selection for subsequent parallel phase III registration studies across multiple Th2 dermatology, gastroenterology and respiratory indications.
Kymera’s Pipeline Progress
The encouraging results from this phase I study demonstrate that KT-621 could achieve robust STAT6 degradation in blood and skin that was well tolerated, and the results surpassed management’s expectations.
The candidate was as effective as Dupixent in eliminating STAT6 in the blood, which raises hopes of a potential success.
Though still in the early phase, the compelling data on KT-621 increases the chances of success in later studies.
Another candidate, KT-474 (SAR444656), is a first-in-class IRAK4 degrader in development for the treatment of immune-inflammatory diseases with significant patient needs, such as hidradenitis suppurativa (HS) and AD.
In collaboration with partner Sanofi, two phase IIb dose-ranging clinical trials for the treatment of HS and AD are ongoing, with primary completion expected in the first half of 2026 for HS and mid-2026 for AD.
Kymera has a sound cash position as well. As of March 31, 2025, KYMR had $775 million in cash, cash equivalents and investments. The company expects its cash and cash equivalents to provide it with an anticipated cash runway into the first half of 2028.
In the past 60 days, estimates for Lexicon’s loss per share have narrowed from 37 cents to 32 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from 35 cents to 31 cents.
LXRX’s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion, delivering an average surprise of 11.97%.
In the past 60 days, estimates for Amarin’s loss per share for 2025 have narrowed from $5.33 to $2.78. During the same time, loss per share estimates for 2026 have narrowed from $4.13 to $2.04.
AMRN’s earnings beat estimates in two of the trailing four quarters, matched once and missed the same on the remaining occasion, delivering an average surprise of 29.11%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
Key Takeaways
Kymera Therapeutics, Inc. (KYMR - Free Report) announced positive clinical results from the phase I study on the investigational candidate, KT-621.
Shares surged as data surpassed the company’s expectations and showed comparable efficacy to Dupixent (dupilumab).
KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Th2 inflammation.
Shares of KYMR have gained 7.2% year to date against the industry’s decline of 2.2%.
Image Source: Zacks Investment Research
More on KYMR’s Study on KT-621
The phase I study was a double-blind, placebo-controlled study that enrolled a total of 118 subjects. The trial consisted of single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. The objective was to evaluate the safety and tolerability of escalating single and multiple ascending daily oral doses of KT-621.
The study also included pharmacokinetic measures as secondary endpoints.
Data showed KT-621 demonstrated a favorable plasma PK profile after single and multiple doses. There was a dose-proportional increase in exposure after multi-dosing, and steady-state was achieved by day four.
The candidate also demonstrated rapid, deep and prolonged STAT6 degradation in blood after single doses of KT-621 and in blood and skin after multiple doses of KT-621.
A greater than 90% mean STAT6 degradation in blood was achieved at all doses above 1.5 mg and complete STAT6 degradation was achieved in both blood and skin at all MAD doses greater than 50 mg.
Data surpassed Kymera’s target product profile, significantly derisking the program and further validating its oral, biologics-like profile.
The impact on Th2 biomarkers was in line or superior to Dupixent with median TARC reduction up to 37% and median Eotaxin-3 reduction up to 63%.
Dupixent is a blockbuster asthma and dermatitis drug being marketed by Sanofi (SNY - Free Report) and Regeneron.
KT-621 was well-tolerated with a safety profile undifferentiated from placebo. There were no serious adverse events, no severe adverse events and no treatment-related adverse events in more than one subject, and no clinically relevant changes in vital signs, lab tests or ECGs.
In April, Kymera initiated dosing in the KT-621 BroADen phase Ib study in moderate to severe atopic dermatitis (AD) patients. Data is expected to be reported in the fourth quarter of 2025. Two parallel phase IIb studies in AD and asthma are set to start in the fourth quarter of 2025 and first quarter of 2026, respectively.
Kymera intends to accelerate KT-621 development and enable dose selection for subsequent parallel phase III registration studies across multiple Th2 dermatology, gastroenterology and respiratory indications.
Kymera’s Pipeline Progress
The encouraging results from this phase I study demonstrate that KT-621 could achieve robust STAT6 degradation in blood and skin that was well tolerated, and the results surpassed management’s expectations.
The candidate was as effective as Dupixent in eliminating STAT6 in the blood, which raises hopes of a potential success.
Though still in the early phase, the compelling data on KT-621 increases the chances of success in later studies.
Another candidate, KT-474 (SAR444656), is a first-in-class IRAK4 degrader in development for the treatment of immune-inflammatory diseases with significant patient needs, such as hidradenitis suppurativa (HS) and AD.
In collaboration with partner Sanofi, two phase IIb dose-ranging clinical trials for the treatment of HS and AD are ongoing, with primary completion expected in the first half of 2026 for HS and mid-2026 for AD.
Kymera has a sound cash position as well. As of March 31, 2025, KYMR had $775 million in cash, cash equivalents and investments. The company expects its cash and cash equivalents to provide it with an anticipated cash runway into the first half of 2028.
KYMR’s Zacks Rank and Stocks to Consider
Kymera currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Lexicon Pharmaceuticals (LXRX - Free Report) and Amarin (AMRN - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Lexicon’s loss per share have narrowed from 37 cents to 32 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from 35 cents to 31 cents.
LXRX’s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion, delivering an average surprise of 11.97%.
In the past 60 days, estimates for Amarin’s loss per share for 2025 have narrowed from $5.33 to $2.78. During the same time, loss per share estimates for 2026 have narrowed from $4.13 to $2.04.
AMRN’s earnings beat estimates in two of the trailing four quarters, matched once and missed the same on the remaining occasion, delivering an average surprise of 29.11%.